Luo Min, Sun Wei, Wu Cheng, Zhang Linli, Liu Dongbo, Li Wenwen, Mei Qi, Hu Guoqing
Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, Wuhan, People's Republic of China.
Oncotarget. 2017 Jun 28;8(40):67651-67662. doi: 10.18632/oncotarget.18798. eCollection 2017 Sep 15.
Gamma-glutamyl transpeptidase (GGT) which plays an important role in tumor initiation, invasion, drug resistance is strongly associated with poor prognosis in patients with cancers. This study was designed to estimate whether pretreatment serum GGT could predict the clinical outcome of nasopharyngeal carcinoma (NPC) patients.
An optimal cutoff value was identified as 23 U/L for GGT. Univariate analysis and multivariate analysis demonstrated that elevated GGT was correlated with shorter local recurrence-free survival (LRFS) (HR, 4.163; 95% CI, 1.690-10.251; p=0.023), progression-free survival (PFS) (HR, 3.119; 95% CI, 1.955-4.976; p=0.031) and overall survival (OS) (HR, 2.811; 95% CI, 1.614-4.896; p=0.007).
We retrospectively analyzed data from 374 patients with NPC. Kaplan-Meier method was used to calculate and compare the prognosis. The Cox proportional hazards model was applied to carry out univariate and multivariate analyses.
Pretreatment GGT can be a novel and independent prognostic biomarker for patients with NPC.
γ-谷氨酰转肽酶（GGT）在肿瘤发生、侵袭及耐药过程中发挥重要作用，与癌症患者的不良预后密切相关。本研究旨在评估治疗前血清GGT是否可预测鼻咽癌（NPC）患者的临床结局。
确定GGT的最佳临界值为23 U/L。单因素分析和多因素分析表明，GGT升高与较短的局部无复发生存期（LRFS）（风险比[HR]，4.163；95%置信区间[CI]，1.690 - 10.251；p = 0.023）、无进展生存期（PFS）（HR，3.119；95% CI，1.955 - 4.976；p = 0.031）和总生存期（OS）（HR，2.811；95% CI，1.614 - 4.896；p = 0.007）相关。
我们回顾性分析了374例NPC患者的数据。采用Kaplan-Meier法计算并比较预后情况。应用Cox比例风险模型进行单因素和多因素分析。
治疗前GGT可作为NPC患者一种新的独立预后生物标志物。
